welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Earlier start of corticosteroids in DMD linked to earlier heart disease onset, study suggests
Researchers say it is important to carefully assess the timing of the start of corticosteroid treatment for Duchenne muscular dystrophy (DMD) in children and its potential association with disease outcomes.
The study, “Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy,” was published in the journal Neuromuscular Disorders.
DMD is an inherited childhood-onset disease characterized by mutations in the DMD gene that provides instructions for making a protein called dystrophin, located primarily in skeletal muscles used for movement and in the heart muscle. These mutations lead to progressive muscle weakness.
rareRelated
-
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular DystrophyThe expanded access program will provide...
-
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of DeflazacortPTC Therapeutics, Inc. today announced t...
-
Has outcome changed for adults with Duchenne muscular dystrophy?We investigated the cause of death, the ...
-
Growth Hormone Increases Bone Toughness and Decreases Muscle Inflammation in Glucocorticoid-Treated Mdx Mice, Model ...The absence of functional dystrophin wit...
-
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients...PTC Therapeutics, Inc. today announced t...
-
Effect of Deflazacort and Prednisone on Muscle Enzymes in the Treatment of Duchenne Muscular DystrophyObjective: To describe the effects of d...
-
Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Gluco...Objective:To evaluate clinical outcomes ...
